Navigation Links
Schering-Plough Reports Financial Results for 2009 Second Quarter
Date:7/21/2009

h and development 906 (2) - - 904 Other expense/(income), net 134 - - - 134 Special and acquisition-related charges 94 - (94) - - Equity income (493) - - 64 (429) ----- - - -- ----- Income before income taxes 502 357 94 (64) 889 Income tax expense/(benefit) 40 (73) (7) - 120 -- ---- --- - --- Net income $462 $284 $87 $(64) $769 ---- ---- === ---- ---- Preferred stock dividends 38 - - - 38 -- - - - -- Net income available to common shareholders $424 $284 $87 $(64) $731 ==== ==== === ==== ==== Diluted earnings per common share $0.26 $0.45 ===== ===== Average shares outstanding common and participating - diluted 1,632 1,632 (1) "As Reconciled" to exclude purchase accounting adjustments, special and acquisition-related items and other specified items.


    SCHERING-PLOUGH CORPORATION

    Reconciliation from Reported Net Income Available to Common Shareholders
    and Reported Diluted Earnings Per Common Share to As Reconciled Amounts
    for Net Income Available to
'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
2. Schering-Plough Announces Pricing of Senior Notes Offering
3. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference
4. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
5. Schering-Plough Completes Acquisition of Organon BioSciences
6. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
11. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 ... pilot study of mazindol in children with attention deficit/hyperactivity ... in December 2014 . The paper, ... with attention deficit/hyperactivity disorder" ( Konofal et al, ... 1;8:2321-2332. eCollection 2014 ) shows that mazindol might ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
(Date:12/22/2014)... CHAPEL HILL, N.C. , Dec. 22, 2014 ... ALNE) today announced that it has signed a ... biotechnology company that has developed and patented a ... and medical diagnostics products that enable rapid on-site ... and alcohol use/abuse and health issues in an ...
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014  ( ... that CoPatient, an online medical bill review and advocacy ... offering in the FREE WellCard Savings discount health services ... medical bill that was more than they expected to ... members reduce health care costs, WellCard Savings is pleased ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2
... and Nanoscience Center (NSC) of the University of Jyvskyl ... the structural, electronic and optical properties of a chiral ... The theoretical structure was confirmed via comparison to experimental ... the pure cluster material. The theoretical work was done ...
... , May 27 Celsis International, the global ... Master Files with the U.S. Food & Drug Administration (FDA) to include ... finished goods on the Celsis system. , ... "A growing number of our Rapid Detection customers are using ...
... ,, (IGEN: OTCBB) , , , ... NV , May 27 /PRNewswire-FirstCall/ - Mr. Richard Gilbertson ... "Developed nations, especially urban areas, ... an international business from a remote location, without connectivity to the rest of ...
Cached Biology Technology:Secrets of a chiral gold nanocluster unveiled 2Celsis Rapid Detection's Updated Drug Master Files (DMFs) Accepted by FDA 2IGEN engages investor relations firm and announces private placement 2IGEN engages investor relations firm and announces private placement 3
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology ... system measures the overall facial feature of a ... the distance between eyes. Facial recognition is used ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a ... while. Hypertension – the medical term for high blood pressure ... 1800s, and the inflatable cuff that,s used in measuring blood ... mean there,s nothing new about hypertension, its triggers and its ... about the condition and the best ways to treat it. ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... The National Institute of Standards and Technology (NIST) has ... ginkgo biloba, one of the most popular dietary supplements ... $1 billion. The NIST reference materials are ... methods for flavonoids and terpene lactones (plant constituents that ...
... PKMzeta maintains long-term memories in the neocortex and ... memory to endure, according to a finding by researchers ... Downstate Medical Center in Brooklyn, New York. The study ... magazine ( www.sciencemag.org ). The title of the paper ...
... dioxide often means danger - too many animals breathing ... exhaling nearby. Mice have a way of detecting carbon ... a special set of olfactory neurons is involved, a ... in atmospheric carbon dioxide may affect animal behavior. The ...
Cached Biology News:Ginkgo SRMs: Tools for product analysis/quality 2Mice use specialized neurons to detect carbon dioxide in the air 2
... mitochondrial transmembrane potential is one of ... following induction of apoptosis. The ... lipophilic cation, termed as MitoLight, as ... a mitochondrial dye that stains mitochondria ...
Sf21 Insect Cells (Frozen) in Max-XP Medium...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... arrays have been developed for affinity ... A variety of ProteinChip chemical surfaces ... to their unique biochemical properties. Each ... side-by-side sample comparison, and the chips ...
Biology Products: